A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women

Maturitas

Volumn 34, Issue 2, 2000, Pages 133-142

  Saure, A ^a   Planellas, J ^b   Poulsen, H K ^c   Jaszczak, P ^d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NV ORGANON   (Netherlands)

^c Sct Josephs Hospital   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Climacteric symptoms; Sequential estradiol; Standard treatment

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; KLIMALET; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AFFECTIVE NEUROSIS; ARTICLE; BREAST DISEASE; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; HEADACHE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MIGRAINE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SWEATING; THERAPY; VAGINA BLEEDING; VERTIGO;

ADMINISTRATION, ORAL; BLOOD PRESSURE; CLIMACTERIC; DESOGESTREL; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; FLUSHING; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; MOOD DISORDERS; PLACEBOS; PROGESTERONE CONGENERS; SWEATING; UTERINE HEMORRHAGE;

EID: 0033969033     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00103-6     Document Type: Article

References (21)

1. Nasr A., Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol. Endocrinol. 12:1998;43-59.
2. Persson I., Adami H.-O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., Schairer C. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens: results of a prospective study. Br. Med. J. 298:1989;147-151.
3. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., Speizer F.E., Hennekens C.H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335:1996;453-461.
4. PEPI Writing Group. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-207.
5. Kloosterboer H.J., Vonk-Noordegraaf C.A., Turpijn E.W. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 38:1988;325-332.
6. Cullberg G, Eriksson O, Knutsson F, Steffensen K. Desogestrel, a new progestational compound. Comparative study with Iynestrenol, performed in ovariectomized women. Acta Obstet Gynecol Scand 1982;Suppl. 111:13-19.
7. Saure A, Hirvonen E, Viinikka L, Ylikorkala O. The effect of a novel sequential estradiol-desogestrel treatment on the bone in postmenopausal women. In: Christiansen C, Overgeard K, editors. Osteoporosis 1990. Aalborg Aps 1990;2:1068-1070.
8. Marslew U., Riis B.J., Christiansen C. Desogestrel in hormone replacement therapy: longterm effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur. J. Clin. Invest. 21:1991;601-607.
9. Haarbo J., Hassager C., Jensen S.B., Riis B.J., Christiansen C. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxy-progesterone derivatives. Am. J. Med. 90:1991;584-589.
10. Marslew U., Riis B., Christiansen C. Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas. 13:1991;7-16.
11. Haarbo J., Christiansen C. Treatment induced cyclic variations in serum lipids, lipoproteins, and apolipoproteins after 2 years of combined hormone replacement therapy: exaggerated cyclic variations in smokers. Obstet. Gynecol. 80:1992;639-644.
12. Saure A, Hirvonen E, Tikkanen M, Viinikka L, Ylikorkala O. Endocrine and metabolic effects of a novel estradiol-desogestrel treatment in postmenopausal women, Ninth International Congress of Endocrinology, Nice 1992;476.
13. Byrjalsen I., Thormann L., Meinecke B., Riis B.J., Christiansen C. Sequential estrogen and progestogen therapy: Assessment of progestational effects on the postmenopausal endometrium. Obstet. Gynecol. 79:1992;523-528.
14. Saure A., Hirvonen E., Tikkanen M.J., Viinikka L., Ylikorkala O. A novel oestradiol desogestrel preparation for hormone replacement therapy: effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas. 16:1993;1-12.
15. Schlemmer A., Hassager C., Delmas P.D., Christiansen C. Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progestogen therapy. Clin. Endocrinol. 40:1994;777-782.
16. Saure A., Hirvonen E., Milsom I., Christensen A., Damber M.-G. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms. Maturitas. 24:1996;111-118.
17. Bradley J.W. Distribution-free Statistical Tests. 1968;68-86 Prentice-Hall, London.
18. Marslew U., Munk-Nielsen N., Nilas L., Riis B.J., Christiansen C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas. 19:1994;225-237.
19. Sherwin B.B. The impact of different doses of estrogen and progestin on mood and sexual behaviour in postmenopausal women. J. Clin. Endocrinol. Metab. 72:1991;336-343.
20. Sherwin B.B. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet. Gynecol. 87:1996;20-26.
21. Holst J., Bäckström T., Hammarbäck S., von Schoultz B. Progestogen addition during oestrogen replacement therapy-effects on vasomotor symptoms and mood. Maturitas. 1:1989;13-20.